Is Seres Therapeutics Inc (MCRB) overvalued? · rev $126.3M
Seres Therapeutics Inc (MCRB) is a biotechnology company listed on US.
This page asks whether Seres Therapeutics Inc (MCRB) looks expensive on cached numbers — not a short thesis.
Latest reported MCRB revenue for 2023-12-31 was $126.3M. Net income was -$113.7M. Revenue was up 1672.2% from 2022-12-31 to 2023-12-31. MCRB currently screens at market cap $109.8M.
MCRB currently screens at market cap $109.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MCRB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MCRB stock page for the full model, not this heading.
Not investment advice.